Clinical Trial Update: The Incidence and Risk Factors of Side Effects During the Initial Phase of Rifater Therapy - a Prospective Study

View source ↗

Summary

A prospective study examining how often side effects occur and what factors increase risk during the initial phase of Rifater therapy for tuberculosis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Tuberculosis

Drugs mentioned

• Rifater (rifampicin/isoniazid/pyrazinamide fixed-dose combination)

Snippet

Sponsor: E-DA Hospital | Conditions: Tuberculosis | Status: UNKNOWN